lundi 24 août 2026
RechercherExplore
fr.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 13, 2026

Small Molecule Innovator API CDMO Market Outlook, 2026-2033 - Lonza Group, Novo Holdings (Catalent) and Thermo Fisher Scientific Lead the Growing Industry

View original at finance.yahoo.com
Small Molecule Innovator API CDMO Market Outlook, 2026-2033 - Lonza Group, Novo Holdings (Catalent) and Thermo Fisher Scientific Lead the Growing Industry Company Logo With a focus on specialty medicines, growth is driven by pharmaceutical needs for cost-effective, efficient production and regulatory compliance via CDM…
Opening lines of the source · short snapshot — read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Small molecule applications constitute over half of specialty sales

    60% confidence

  • Only 11% of APIs are based in the U.S., with most sourced internationally

    60% confidence

  • By February 2024, the global tally of registered clinical trials on ClinicalTrials.gov reached 483,592, marking a significant rise from the over 365,000 reported in early 2021. Of these, 66,206 trials are actively recruiting

    60% confidence

  • Market expansion is fueled by a growing demand for small molecule drugs, an increase in outsourcing trends among pharmaceutical companies, and a surge in clinical trials

    60% confidence

  • The global small molecule innovator API CDMO market is projected to expand significantly, with an estimated size of USD 26.66 billion in 2025, expected to reach USD 43.75 billion by 2033, growing at a CAGR of 6.55% from 2026 to 2033

    60% confidence

Data points we hold from this source

U.S. Food and Drug Administration · drug approvals46 novel_drugs
U.S. Food and Drug Administration · drug approvals50 novel_drugs
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Notre lecture des données ›
Signaux que nous suivons
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Tendances que nous surveillons ›
Là où les sources divergent
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,978
faits reliés à leur source — et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,978 faits vérifiés avec la source5,251 documents sources archivés
Interrogez ces données → isubstrate.com
Small Molecule Innovator API CDMO Market Outlook, 2026-2033 - Lonza Group, Novo Holdings (Catalent) and Thermo Fisher Scientific Lead the Growing Industry — Source | Via News | fr.VIA.NEWS